Connect your AI

Vivani Medical VANI Stock-Based Comp

Stock-Based Comp at other companies

Eli LillyLLY

$161M+4.5%

AmgenAMGN

$75M-11.8%

AltimmuneALT

$3.38M-15.9%

Viking TherapeuticsVKTX

$10.34M-8.9%

Wave Life SciencesWVE

$9.06M+83.0%

Prime MedicinePRME

$4.64M-18.3%

Other financials

Income statement

Revenue-—

Gross profit$130.0K—

Operating income-$6.8M-4.0%

Net income-$6.8M-7.6%

EPS (diluted)-$0.08+27.3%

Balance sheet

Cash & equivalents$19.0M+57.7%

Total debt$18.3M-3.5%

Total equity$19.1M+64.2%

Total assets$42.4M+19.5%

Cash flow

Operating cash flow-$6.2M-20.0%

CapEx$3.0K-40.0%

Free cash flow-$6.2M-19.9%

Valuation

Market cap$106.93M+40.0%

Enterprise value$106.17M+19.3%

Profitability

Gross margin36.3%—

Operating margin-1,004.9%—

Net margin-994.1%—

FCF margin-832.3%—

Returns & leverage

Return on equity-176.4%+175pp

Debt / equity1×-0.7×

Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vivani Medical's stock-based comp?: Vivani Medical (VANI) reported stock-based comp of $312K in Q1 2026.
How has Vivani Medical's stock-based comp changed year-over-year?: Vivani Medical's stock-based comp decreased by 10.9% year-over-year, from $350K to $312K.
What is the long-term trend for Vivani Medical's stock-based comp?: Over 4 years (2021 to 2025), Vivani Medical's stock-based comp has grown at a -2.9% compound annual growth rate (CAGR), from $1.67M to $1.48M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.